Moderna gets funding for H5 pandemic influenza vaccine

The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government ...

Moderna receives $54.3M investment for bird flu vaccine, covering axed federal mRNA contracts

Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research ...

Moderna gets $54.3 million investment for bird flu vaccine

The Coalition for Epidemic Preparedness Innovations said it will invest $54.3 million with Moderna to fund a Phase 3 trial of ...

Moderna secures up to $54.3 million funding for bird flu vaccine from global coalition

Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental ...
Zacks Investment Research on MSN

MRNA to get CEPI funding for Phase III study on pandemic influenza jab

Moderna MRNA announced that the Coalition for Epidemic Preparedness Innovations (“CEPI”) will invest up to $54.3 million in ...

CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate

Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure ...

Moderna granted up to $54.3M from CEPI for bird flu vaccine

Moderna (MRNA) stock is in focus as CEPI vaccine coalition agreed to invest up to $54.3M to support a late-stage trial for the company's bird flu shot. Read more here.

Moderna gets funding for bird flu shot after HHS ends contract

Moderna Inc. will get as much as $54.3 million for a late-stage trial of its bird flu vaccine in a sign of how outside groups ...
Global News - Inquirer.net on MSN

South Korea commits $18.9 million to global pandemic preparedness

South Korea’s Ambassador to Norway Seo Min-jeong (left) and Richard Hatchett, CEO of the Coalition for Epidemic Preparedness ...

ANZ set for second strike as investors demand more accountability

Another black mark against the bank’s remuneration report will see it join major rival Westpac in having raised the ire of ...

Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®

IXCHIQ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV) Antibody levels remained high after twelve months in both dose groups, ...